$1.60
+0.15 (+10.34%)
Open$1.45
Previous Close$1.45
Day High$1.61
Day Low$1.45
52W High$45.41
52W Low$28.67
Volume—
Avg Volume305.2K
Market Cap208.29M
P/E Ratio17.15
EPS$2.26
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+2,465.0% upside
Current
$1.60
$1.60
Target
$41.04
$41.04
$30.97
$41.04 avg
$66.83
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 29.94M | 31.11M | 33.06M |
| Net Income | -8,740,072 | -8,350,078 | -10,285,734 |
| Profit Margin | -29.2% | -26.8% | -31.1% |
| EBITDA | -14,130,650 | -13,566,183 | -16,328,398 |
| Free Cash Flow | -7,098,906 | -8,976,737 | -6,780,942 |
| Rev Growth | -9.8% | +19.5% | +23.6% |
| Debt/Equity | 0.25 | 0.28 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |